Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Yap mediates hippo signaling to balance proliferation and differentiation in the developing glandular stomach epithelium.

Cell reports·2026
Same author

Generating Tumor Organoid Cultures from the Lung Adenocarcinoma Cell Line.

Journal of visualized experiments : JoVE·2026
Same author

Graft survival and rejection with repeated human leukocyte antigen (HLA) mismatch in kidney transplantation: a retrospective multicentre cohort study protocol.

BMC nephrology·2026
Same author

Human Cardiac Organoids Reveal Anti-Fibrotic Therapeutic Potential of JAK1/2 Inhibition Following Cryogenic Injury.

Phenomics (Cham, Switzerland)·2026
Same author

Elucidating Tumorigenesis Mechanisms and Assessing Immunotherapeutic Efficacy in Patient-Derived Medulloblastoma Organoid Models.

International journal of biological sciences·2026
Same author

Znhit1-mediated H2A.Z deposition governs transcriptional programs essential for oocyte meiotic progression.

Development (Cambridge, England)·2026
Same journal

The role of the epidermal growth factor in the pathogenesis of schizophrenia. Clinical and diagnostic value.

Growth factors (Chur, Switzerland)·2026
Same journal

The role of ERK signaling pathway in pituitary adenomas: from molecular mechanisms to targeted therapy.

Growth factors (Chur, Switzerland)·2026
Same journal

Role of soluble EGFR, Fas, and Fas ligand in pelvic pain severity and their association with endometriosis in infertile woman: a case-control study.

Growth factors (Chur, Switzerland)·2026
Same journal

ErbB receptor stimulation is required for mouse Colon adenoma organoids to form crypts.

Growth factors (Chur, Switzerland)·2026
Same journal

Chorioallantoic membrane assay demonstrating pro-angiogenic properties of BRAF inhibitor: a tool to treat chronic wounds.

Growth factors (Chur, Switzerland)·2026
Same journal

Extracellular matrix biomarkers and transforming growth factor-β in hypertrophic cardiomyopathy: interaction between biomarkers.

Growth factors (Chur, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: May 23, 2026

Covalent Binding of BMP-2 on Surfaces Using a Self-assembled Monolayer Approach
10:23

Covalent Binding of BMP-2 on Surfaces Using a Self-assembled Monolayer Approach

Published on: August 26, 2013

B2A as a positive BMP receptor modulator.

Xinhua Lin1, Henry Guo, Kazuyuki Takahashi

  • 1BioSurface Engineering Technologies, Inc., Rockville, MD 20850, USA. xlin@biosetinc.com

Growth Factors (Chur, Switzerland)
|March 28, 2012
PubMed
Summary
This summary is machine-generated.

The synthetic peptide B2A selectively enhances bone morphogenetic protein (BMP)-2 activity by binding to its receptors, promoting osteodifferentiation for improved bone repair. Its full structure is crucial for this BMP-2 specific effect.

More Related Videos

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
11:20

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry

Published on: March 29, 2018

Related Experiment Videos

Last Updated: May 23, 2026

Covalent Binding of BMP-2 on Surfaces Using a Self-assembled Monolayer Approach
10:23

Covalent Binding of BMP-2 on Surfaces Using a Self-assembled Monolayer Approach

Published on: August 26, 2013

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
11:20

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry

Published on: March 29, 2018

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Regenerative Medicine

Background:

  • Bone morphogenetic protein (BMP)-2 is crucial for osteodifferentiation and bone repair.
  • Synthetic peptides are being explored to augment BMP-2 activity in orthopedic applications.
  • B2A is a multi-domain peptide designed to enhance BMP-2 signaling.

Purpose of the Study:

  • To investigate the mechanism of action of the synthetic peptide B2A.
  • To determine the selectivity of B2A's effect on BMP-2 and other growth factors.
  • To identify the functional domains of B2A essential for its bioactivity.

Main Methods:

  • In vitro assays to assess cell responsiveness and osteodifferentiation.
  • Binding studies to identify BMP receptors interacting with B2A.
  • Dose-response experiments to evaluate the effect of B2A on BMP-2 EC50.
  • Functional domain deletion analysis of B2A.

Main Results:

  • B2A binds to BMP receptor (BMPR)-IB, BMPR-II, and BMPR-IA.
  • B2A reduces the EC50 of recombinant human BMP-2 (rh-BMP-2), enhancing osteogenic activity.
  • B2A's enhancement is specific to BMP-2, not affecting GDF-5, BMP-7, BMP-9, Wnt-3a, or retinoic acid.
  • All three domains of B2A are necessary for its optimal bioactivity.

Conclusions:

  • B2A acts as a positive receptor modulator, selectively enhancing BMP-2-induced osteodifferentiation.
  • The peptide's mechanism involves direct interaction with BMP receptors.
  • B2A demonstrates potential for augmenting bone repair strategies by boosting endogenous BMP-2 signaling.